Daewoong Pharmaceutical Co., Ltd. (069620) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daewoong Pharmaceutical Co., Ltd. (069620:KRX), powered by AI.

Current Price
₩154,100
P/E Ratio
71.7
Market Cap
1.8T
Sector
Healthcare
What is the Daewoong Pharmaceutical Co., Ltd. stock price forecast?

Daewoong Pharmaceutical Co., Ltd. is currently trading at ₩154,100. View real-time AI analysis on Alpha Lenz.

What is Daewoong Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Daewoong Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Daewoong Pharmaceutical Co., Ltd.'s P/E ratio?

Daewoong Pharmaceutical Co., Ltd.'s P/E ratio is 71.7.

Daewoong Pharmaceutical Co., Ltd.

KRX · 069620
₩154,100
Ask about Daewoong Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Daewoong Pharmaceutical Co., Ltd. trades at a P/E of 71.7 (premium valuation) with modest ROE of 3.1%.

Ask for details

Company Overview

Daewoong Pharmaceutical Co., Ltd. is a leading South Korean company in the pharmaceutical industry, focusing on the development, production, and distribution of medicinal drugs. With a strong emphasis on research and innovation, Daewoong is dedicated to creating advanced pharmaceuticals and medical devices that enhance healthcare solutions. The company's product portfolio includes prescription medicines aimed at treating chronic diseases, over-the-counter drugs, and biotechnology-driven therapies. It serves a wide array of sectors including hospital and retail pharmacies, contributing significantly to therapeutic advancements. Daewoong Pharmaceutical's commitment to innovation is evident through its substantial investments in R&D, fostering the development of novel drugs and treatments. The company leverages cutting-edge biotechnology and collaboration with global partners to ensure the delivery of high-quality healthcare solutions. Market presence across Asia and strategic expansion into new territories underscores its role as a pivotal player in the global pharmaceutical landscape. Harnessing technological advancements, Daewoong continues to enhance its product offerings and boost accessibility to healthcare, further cementing its market significance and reputation as a trusted healthcare provider.

CEO이창재, 박성수
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,644

Company Statistics

FY 2024

Profile

₩1,785,491,207,500Market Cap
₩1,422,683,296,380Revenue
11.59MShares Out
1,644Employees

Margins

51.60%Gross
11.20%EBITDA
10.40%Operating
3.97%Pre-Tax
1.64%Net

Valuation

71.69P/E
2.23P/B
1.25EV/Sales
15.39EV/EBITDA
-9.99P/FCF

Growth (CAGR)

7.26%Rev 3Yr
5.02%Rev 5Yr
18.58%Op Inc 3Yr
27.05%Op Inc 5Yr
-8.10%Net Inc 3Yr
-4.16%Net Inc 5Yr

Returns

1.32%ROA
3.10%ROE
3.59%ROIC

Financial Health

₩102,950,420,360Cash & Cash Equivalents
₩947,042,085,000Net Debt
113.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daewoong Pharmaceutical Co., Ltd. (ticker: 069620) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,644 employees. Market cap is $1.8T.

The current price is ₩154,100 with a P/E ratio of 71.69x and P/B of 2.23x.

ROE is 3.10% and operating margin is 10.40%. Annual revenue is $1.4T.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daewoong Pharmaceutical Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩154,100 | Alpha Lenz